| Clinical data | |
|---|---|
| Other names | 4,17β-Dihydroxyandrost-4-en-3-one; Androst-4-ene-4,17β-diol-3-one; Desmethylenestebol |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H28O3 |
| Molar mass | 304.430 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
4-Hydroxytestosterone (4-OHT), also known as4,17β-dihydroxyandrost-4-en-3-one, is asyntheticanabolic-androgenic steroid (AAS) and aderivative oftestosterone that was never marketed. It was first patented byG.D. Searle & Company in 1955[1] and istestosterone with a hydroxy group at the four position. 4-OHT has moderateanabolic, mildandrogenic, andanti-aromatase properties and is similar to the steroidclostebol (4-chlorotestosterone).[2]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byadding missing information. |